Dorothy Lou Bailey

Dorothy Lou Bailey has extensive work experience in various roles within the biotechnology and healthcare industries. Dorothy Lou is currently the Chief Operating Officer and President at Exo Therapeutics since July 2022. Prior to this, they served as the Senior Vice President of Corporate Development and Strategy at Exo Therapeutics from October 2021 to December 2022.

Before joining Exo Therapeutics, Dorothy worked as a Corporate Development and Strategy Consultant for multiple companies from June 2020 to October 2021. Dorothy Lou also held positions at BlackThorn Therapeutics, serving as the Senior Director and Head of Corporate Development from May 2018 to June 2020, and as the Director of Business Development and Strategy from October 2016 to May 2018.

Dorothy's earlier experiences include serving as the Principal Consultant at The Reckon Group from July 2014 to December 2016, and as the Business Lead and Advisor at Myriad Sensors, Inc. from October 2014 to November 2016. Dorothy Lou also worked as the Interim Head of Business Development at Transcriptic from January 2015 to January 2016, and as the Bay Area Director at BlueStamp Engineering from January 2015 to June 2015.

Additionally, Dorothy has held roles at Science Exchange, where they worked as the Director of Partnerships and Funding from March 2014 to November 2014, and as the Business Development Manager from December 2013 to March 2014. Dorothy Lou was also a Research Fellow at Rock Health from August 2013 to December 2013.

Dorothy's earliest work experience was at Pureflowinc, where they served as the Life Science Liaison from an unknown start date to June 2013. In this role, they led a cross-disciplinary team in creating product redesign and new business strategies, resulting in a 13% revenue growth.

Overall, Dorothy Lou Bailey has a diverse background in roles ranging from business development and corporate strategy to consulting and executive leadership.

Dorothy Lou Bailey attended Duke University from 2003 to 2007, where they obtained a Bachelor of Science degree in Biochemistry and Molecular Biology. After completing their undergraduate degree, there is no further information available about their education at Stanford University or Startuponomics.